Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain

Selegiline (L-deprenyl) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10 mg/day oral) that is used in the treatment of Parkinson's disease. However, controlled studies have demonstrated antidepressant activity for high doses of oral selegiline a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fowler, Joanna S, Logan, Jean, Volkow, Nora D, Shumay, Elena, McCall-Perez, Fred, Jayne, Millard, Wang, Gene-Jack, Alexoff, David L, Apelskog-Torres, Karen, Hubbard, Barbara, Carter, Pauline, King, Payton, Fahn, Stanley, Gilmor, Michelle, Telang, Frank, Shea, Colleen, Xu, Youwen, Muench, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289953/
https://www.ncbi.nlm.nih.gov/pubmed/25249059
http://dx.doi.org/10.1038/npp.2014.214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289953/
https://www.ncbi.nlm.nih.gov/pubmed/25249059
http://dx.doi.org/10.1038/npp.2014.214

Ejemplares similares